PrecigenSTU:I5X -4.53%65 Days Payable is 257.06 as of Mar. 2026, which is 35% above its 10-year median of 189.76. GuruFocus rates STU:I5X with a GF Score™ of 65/100 and a GF Value™ of €5.15 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 701 Biotechnology companies, Precigen ranks better than 72.61% on this metric.
Precigen's average Accounts Payable for the
three
months ended in Mar. 2026 was €6.24 Mil. Precigen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2.21 Mil.
Hence, Precigen's Days Payable for the
three
months ended in Mar. 2026 was 257.06.
The historical rank and industry rank for Precigen's Days Payable or its related term are showing as below:
STU:I5X'
s Days Payable Range Over the Past 10 Years
Min: 33.29 Med: 189.76 Max: 594.33
Current: 323.81
During the past 13 years, Precigen's highest Days Payable was 594.33. The lowest was 33.29. And the median was 189.76.
STU:I5X's Days Payable is ranked better than 72.61% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs STU:I5X: 323.81
Precigen's Days Payable
declined
from Mar. 2025 (280.21) to Mar. 2026 (257.06).
It may suggest that Precigenaccelerated paying its suppliers.
Precigen Days Payable Related Terms
Precigen Days Payable Historical Data
* Premium members only.
The historical data trend for Precigen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:I5X vs KARD, SLBT, GENB: Days Payable Comparison
For the Biotechnology subindustry, Precigen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's Days Payable distribution charts can be found below:
* The bar in red indicates where Precigen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Precigen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (STU:I5X) has a Days Payable of 257.06 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Precigen and its competitors. This is 35% above median its historical median of 189.76. Over the past decade, Precigen's Days Payable has ranged from 33.29 to 594.33. According to the industry distribution chart, Precigen ranks #192 out of 701 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Precigen's Days Payable too high?
Precigen's current Days Payable of 257.06 is 35% above median its 10-year median of 189.76. Over the past 10 years, this metric has ranged from a low of 33.29 to a high of 594.33. The Biotechnology industry median Days Payable is 112.84. Precigen's value of 257.06 is 127.8% above this industry median. Based on the distribution chart, Precigen ranks #192 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Precigen has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Days Payable compare to KARD and SLBT?
According to the Biotechnology industry distribution chart, Precigen ranks #192 out of 701 companies for Days Payable. This puts Precigen in the upper half of its industry. The industry median Days Payable is 112.84. Precigen's value of 257.06 is 127.8% above this benchmark. Historically, Precigen's own Days Payable has ranged from 33.29 to 594.33 over the past decade. While the company's 10-year median is 189.76 vs. the industry median of 112.84, Precigen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precigen's current Days Payable of 257.06 is 127.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Precigen and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precigen's current Days Payable is 257.06, which is 35% above median its own 10-year median of 189.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.15, compared to a current price of €4.64 — trading 9.9% below its estimated fair value. The current Days Payable is 257.06, which is 35% above median its 10-year median of 189.76 and 127.8% above the Biotechnology industry median of 112.84. Precigen's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Precigen (STU:I5X), the current Days Payable is 257.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (STU:I5X) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be undervalued.
The current stock price of €4.64 is trading 9.9% below its estimated GF Value™ of €5.15.
GuruFocus considers Precigen to be Modestly Undervalued.
Key valuation signals for STU:I5X:
Days Payable: 257.06 (35% above median its 10-year median of 189.76)
GF Value™: €5.15 vs. price of €4.64 (9.9% below fair value)
Industry Position: 127.8% above the Biotechnology median (#192 of 701)
No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
65GF Score
Get the complete analysis for STU:I5X
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I5X has been successfully added to your 
